Uterine leiomyomas are benign tumors arising from the myometrium and largely prevalent in the woman's reproductive years. The majority of women with leiomyomas either remain asymptomatic or develop symptoms gradually over time. When patients are symptomatic, the nature of their complaints is often attributable to the number, size, and/or location of their fibroids. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy).
PRINCIPLE OF TREATMENT
The management of uterine leiomyomas varies In the short term, COCs can be used to improve heavy menstrual bleeding associated with fibroids, primarily through their suppressive effects on endometrial proliferation, but overall they have no effect on decreasing leiomyoma volume or uterine size. 2 The advantages of COCs are the ease of accessibility, oral administration, low cost, and minimal side-effect profile. However, generally, COCs are not recommended for the treatment of abnormal uterine bleeding or bulk symptoms associated with leiomyomas, and patients should be offered alternative therapies for symptomatic relief. 
GONADOTROPIN-RELEASING HORMONE (GnRH) AGONIST
GnRH agonists were one of the first medical therapies to be used in the treatment of leiomyomas. In 1999, the FDA approved the short-term use of leuprolide acetate as a preoperative adjunct in women with symptomatic leiomyomas. 3 Treatment with GnRH-a decreases uterine volume, fibroid volume, and bleeding.
However, the benefits of GnRH-a are limited by side effects and risks associated with long term use. Hgh doses are associated with hypoestrogenism, leading to decreased bone mineral density. 
SELECTIVE ESTROGEN RECEPTOR MODUL-ATORS(SERMs)
Selective
MIFEPRISTONE (RU-486)
Mifepristone is a synthetic 19-norsteroid SPRM with primarily PR antagonist activity, and was one of the first SPRMs to be developed and commonly 
